Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
1. 4,6-diamino-(1,2-dihydro)-2,2-dimethyl-1-(2,4,5-trichlorophenoxypropyloxy)-1,3,5-triazine.hcl
2. Brl 51084
3. Brl 6231
4. Brl 6231hydrochloride
5. Brl 6231mono-hydrobromide
6. Brl-51084
7. Brl-6231
8. Unspecified Hcl Of Brl 6231
9. Wr 99210
10. Wr-99210
11. Wr99210-hcl
1. Wr99210
2. 47326-86-3
3. Wr-99210
4. 1,3,5-triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-
5. Brl 6231
6. Chembl129788
7. Wr 99210
8. 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine
9. 1,6-dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine
10. 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine
11. 6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)propoxy)-1,6-dihydro-1,3,5-triazine-2,4-diamine
12. 1,3,5-triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)propoxy)-
13. Wra
14. Brn 0629517
15. Wr-99,210
16. 1-(2',4',5'-trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine
17. 1,6-dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)propoxy)-1,3,5-triazine-2,4-diamine, Monohydrochloride
18. Schembl8635467
19. Bdbm18793
20. Dtxsid30952947
21. Xba32686
22. Zinc3581056
23. Wr-99209 (*hydrogen Bromide*)
24. Brl 6231 (*monohydrogen Chloride*)
25. Db08734
26. 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazinane-2,4-diimine
27. 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-[(2,4,5-trichlorophenoxy)propyloxy]-1,3,5-triazine
28. Hy-116387
29. Cs-0065315
30. Q27467334
31. 2,2-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-4,6-diamine
32. 4-imino-6,6-dimethyl-5-[3-(2,4,5-trichlorophenoxy)propoxy]-1h-1,3,5-triazin-2-amine
Molecular Weight | 394.7 g/mol |
---|---|
Molecular Formula | C14H18Cl3N5O2 |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 6 |
Exact Mass | 393.052608 g/mol |
Monoisotopic Mass | 393.052608 g/mol |
Topological Polar Surface Area | 98.5 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 503 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Folic Acid Antagonists
Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)
Antimalarials
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
Patent Expiration Date : 2021-08-07
Date Granted : 2009-11-03
Brand Name : STELARA
Patent Number : 2418961
Filing Date : 2001-08-07
Strength per Unit : 45 mg / 0.5 mL
Dosage Form : Solution (Vial) / Solution (pre-filled syringe)
Human Or VET : Human
Route of Administration : Subcutaneous Injection
Patent Expiration Date : 2021-08-07
Date Granted : 2009-11-03
Patent Expiration Date : 2021-08-07
Date Granted : 2009-11-03
Brand Name : STELARA
Patent Number : 2418961
Filing Date : 2001-08-07
Strength per Unit : 90 mg / 1.0 mL
Dosage Form : Solution (Vial) / Solution (pre-filled syringe)
Human Or VET : Human
Route of Administration : Subcutaneous Injection
Patent Expiration Date : 2021-08-07
Date Granted : 2009-11-03
Patent Expiration Date : 2021-08-07
Date Granted : 2009-11-03
Brand Name : STELARA I.V.
Patent Number : 2418961
Filing Date : 2001-08-07
Strength per Unit : 5 mg / mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : INTRAVENOUS
Patent Expiration Date : 2021-08-07
Date Granted : 2009-11-03
ABOUT THIS PAGE
A Ustekinumab manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ustekinumab, including repackagers and relabelers. The FDA regulates Ustekinumab manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ustekinumab API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ustekinumab manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ustekinumab supplier is an individual or a company that provides Ustekinumab active pharmaceutical ingredient (API) or Ustekinumab finished formulations upon request. The Ustekinumab suppliers may include Ustekinumab API manufacturers, exporters, distributors and traders.
click here to find a list of Ustekinumab suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Ustekinumab Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ustekinumab GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ustekinumab GMP manufacturer or Ustekinumab GMP API supplier for your needs.
A Ustekinumab CoA (Certificate of Analysis) is a formal document that attests to Ustekinumab's compliance with Ustekinumab specifications and serves as a tool for batch-level quality control.
Ustekinumab CoA mostly includes findings from lab analyses of a specific batch. For each Ustekinumab CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ustekinumab may be tested according to a variety of international standards, such as European Pharmacopoeia (Ustekinumab EP), Ustekinumab JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ustekinumab USP).
LOOKING FOR A SUPPLIER?